DprE1-IN-9 (compound B18) is an efficient reversible inhibitor of DprE1, interacting with the enzyme's receptor cavity. It exhibits potent antimycobacterial properties, demonstrating activity against both non-pathogenic H37Ra (MIC=0.18 µg/mL) and pathogenic strains, including H37Rv, as well as clinical MDR and XDR isolates [1].